PubMed Health⌕ Search

Biomedical subjects

K Kamolpatana

Publications and source records attributed to K Kamolpatana.

3 recordsLinked to original sources

Prostatic disorders in the dog.

Common canine prostatic disorders include benign prostatic hypertrophy (BPH), prostatitis, prostatic cysts and prostatic adenocarcinoma. BPH is a spontaneous and age-related disorder of intact male dogs, which occurs in more than 80% male dogs over 5 years of age, and which is associated with clinical signs of sanguinous prostatic fluid, constipation and dysuria. BPH signs respond to castration or to finasteride treatment (0.1-0.5 mg/kg per os once daily), as finasteride inhibits conversion of testosterone to dihydrotestosterone, causing prostatic involution via apoptosis. BPH often occurs concurrently with prostatic infection, abscessation, cysts and neoplasia in the intact dog, and finasteride-induced prostatic involution may be beneficial in treatment of all of these conditions except neoplasia. Two studies suggest that risk of prostatic adenocarcinoma is increased in neutered, compared to intact male dogs. Although canine prostatic neoplasia, unlike human prostatic neoplasia, usually does not respond to androgen deprivation, recent reports of prostatic intraepithelial neoplasia (PIN) in a high percentage of older male dogs, with and without prostatic adenocarcinoma, suggests that PIN may be a precursor to adenocarcinoma in the dog as it is believed to be in man.

Adenocarcinoma↗

Effect of finasteride on serum concentrations of dihydrotestosterone and testosterone in three clinically normal sexually intact adult male dogs.

OBJECTIVE: To determine the effect of finasteride at dosages of 0, 10, 0.25, and 0.50 mg/kg of body weight, PO, q 24 h, for 7 days) in a Latin square design with repeated measures. Blood was obtained before and on days 1, 2, 4, and 7 of treatment; 3 blood samples were obtained at 20 minute intervals to detect pulsatile secretion of DHT and T. Dogs were untreated at least 2 weeks between treatments. RESULTS: Finasteride at all doses was associated with a mean decrease in concentration of DHT of 55% (range, 155 +/- 32.3 pg/ml to 70 +/- 15 pg/ml), but had no effect on concentration of T (before treatment, 2.6 +/- 0.38 ng/ml; after treatment, 2.2 +/- 0.63 ng/ml). CONCLUSIONS: Finasteride at these doses significantly decreased serum concentration of DHT in sexually intact adult male dogs. Concentrations of DHT and T before and 7 days after treatment did not differ by dosage of finasteride administered. CLINICAL RELEVANCE: Finasteride (5 mg; 1 tablet) may be a drug of choice for treatment of benign prostatic hypertrophy in 10- to 50-kg dogs.

Analysis of Variance↗

Determination of canine prostatic volume using transabdominal ultrasonography.

The prostate gland from cadavers of 12 intact adult male dogs euthanized less than 3 hour were used to compare prostatic volume measured by ultrasonography to volume measured by water displacement, and to determine specific gravity of the canine prostate. Prostate glands were scanned by transabdominal ultrasonography with a 4-7 MHz curved linear array transducer. The greatest craniocaudal (L), transverse (W), and dorsoventral (D) diameters of the prostate were recorded. Prostatic volume was calculated using formulas for an ellipsoid and for a box. Prostate glands were removed, and the prostate weight was measured and prostatic volume was measured by water displacement. The mean +/- SD specific gravity of the prostate was 1 +/- 0.05 (range = 0.90 to 1.09) g/cm. There were positive correlations (R2 = 0.94) between prostatic volume calculated from ultrasound measurement and measured volume. Measured prostatic volume (VM) can be predicted using the formula: VM = [1/2.6 (L x W x D)] + 1.8 (cm3).

Algorithms↗